SI3097119T1 - Človeška protitelesa proti PD-1 - Google Patents

Človeška protitelesa proti PD-1

Info

Publication number
SI3097119T1
SI3097119T1 SI201531692T SI201531692T SI3097119T1 SI 3097119 T1 SI3097119 T1 SI 3097119T1 SI 201531692 T SI201531692 T SI 201531692T SI 201531692 T SI201531692 T SI 201531692T SI 3097119 T1 SI3097119 T1 SI 3097119T1
Authority
SI
Slovenia
Prior art keywords
human antibodies
antibodies
human
Prior art date
Application number
SI201531692T
Other languages
English (en)
Inventor
Nicholas J. Papadopoulos
Andrew J. Murphy
Gavin Thurston
Ella Ioffe
Elena Burova
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3097119(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of SI3097119T1 publication Critical patent/SI3097119T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SI201531692T 2014-01-23 2015-01-23 Človeška protitelesa proti PD-1 SI3097119T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461930576P 2014-01-23 2014-01-23
US201462014181P 2014-06-19 2014-06-19
PCT/US2015/012589 WO2015112800A1 (en) 2014-01-23 2015-01-23 Human antibodies to pd-1
EP15703187.3A EP3097119B1 (en) 2014-01-23 2015-01-23 Human antibodies to pd-1

Publications (1)

Publication Number Publication Date
SI3097119T1 true SI3097119T1 (sl) 2021-11-30

Family

ID=52462456

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531692T SI3097119T1 (sl) 2014-01-23 2015-01-23 Človeška protitelesa proti PD-1

Country Status (30)

Country Link
US (3) US9987500B2 (sl)
EP (2) EP3967710A1 (sl)
JP (4) JP6425730B2 (sl)
KR (2) KR20210152583A (sl)
CN (2) CN106068275B (sl)
AU (1) AU2015209233B2 (sl)
BR (2) BR112016016699A2 (sl)
CA (2) CA3207270A1 (sl)
CL (1) CL2016001871A1 (sl)
CY (1) CY1124747T1 (sl)
DK (1) DK3097119T3 (sl)
EA (1) EA034770B8 (sl)
ES (1) ES2888224T3 (sl)
HR (1) HRP20211794T1 (sl)
HU (1) HUE056332T2 (sl)
IL (2) IL246818B (sl)
LT (1) LT3097119T (sl)
MX (3) MX2016009554A (sl)
MY (1) MY176475A (sl)
NZ (1) NZ722342A (sl)
PH (1) PH12016501330A1 (sl)
PL (1) PL3097119T3 (sl)
PT (1) PT3097119T (sl)
RS (1) RS62507B1 (sl)
SG (1) SG11201605482SA (sl)
SI (1) SI3097119T1 (sl)
TW (1) TWI681969B (sl)
UA (1) UA122666C2 (sl)
UY (1) UY35964A (sl)
WO (1) WO2015112800A1 (sl)

Families Citing this family (495)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ725006A (en) 2014-03-12 2019-11-29 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2017042633A2 (en) * 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US9982053B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
EP3984542A1 (en) * 2014-11-20 2022-04-20 Promega Corporation Systems and methods for assessing modulators of immune checkpoints
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN114380909A (zh) 2015-03-30 2022-04-22 斯特库比股份有限公司 特异性针对糖基化的pd-l1的抗体及其使用方法
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
CN108136001B (zh) 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TW201709929A (zh) 2015-06-12 2017-03-16 宏觀基因股份有限公司 治療癌症的聯合療法
EA201890285A1 (ru) 2015-07-13 2018-08-31 Сайтомкс Терапьютикс, Инк. Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CN116059219A (zh) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
EP3328419B1 (en) 2015-07-30 2021-08-25 MacroGenics, Inc. Pd-1-binding molecules and methods of use thereof
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP2018526989A (ja) 2015-08-07 2018-09-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ−３およびｐｄ−１に特異的な新規融合ポリペプチド
CA2993276A1 (en) 2015-08-11 2017-02-16 Yong Zheng Novel anti-pd-1 antibodies
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN107949573B (zh) * 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
JP7023231B2 (ja) 2015-09-23 2022-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 最適化抗ｃｄ３二重特異性抗体及びその使用
ES2907486T3 (es) * 2015-09-24 2022-04-25 Univ North Carolina Chapel Hill Métodos y composiciones para reducir metástasis
MX2018003689A (es) 2015-09-29 2018-04-30 Celgene Corp Proteinas de union a pd-1 y metodos para usarlas.
WO2017058115A1 (en) 2015-09-29 2017-04-06 Asia Biotech Pte. Ltd. Pd-1 antibodies and uses thereof
KR102146319B1 (ko) 2015-10-02 2020-08-25 에프. 호프만-라 로슈 아게 Pd1 및 tim3에 특이적인 이중특이성 항체
MY190324A (en) 2015-10-02 2022-04-14 Symphogen As Anti-pd-1 antibodies and compositions
MA45429A (fr) 2015-10-08 2019-05-01 Macrogenics Inc Polythérapie pour le traitement du cancer
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
MA43186B1 (fr) * 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
TW202216787A (zh) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及／或 lag3結合劑
CN106699889A (zh) * 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
KR20180085793A (ko) * 2015-12-02 2018-07-27 주식회사 에스티큐브 글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법
AU2016370376B2 (en) 2015-12-14 2023-12-14 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
MA44146B1 (fr) * 2015-12-22 2023-10-31 Regeneron Pharma Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
CN105669864B (zh) * 2015-12-23 2018-10-16 杭州尚健生物技术有限公司 抗人程序性死亡受体1抗体及其制备方法和用途
EP3405499A4 (en) * 2016-01-21 2020-03-18 The Board of Trustees of the Leland Stanford Junior University TREATING CANCER WITH COMBINATIONS OF IMMUNE REGULATORS
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
CN109311981B (zh) * 2016-01-22 2022-08-23 马布奎斯特公司 Pd1特异性抗体
US11513127B2 (en) 2016-01-25 2022-11-29 Genentech, Inc. Methods for assaying T-cell dependent bispecific antibodies
US11180546B2 (en) 2016-02-17 2021-11-23 Novartis Ag TGFbeta 2 antibodies
BR112018067458A2 (pt) 2016-03-04 2019-01-02 Abmuno Therapeutics Llc anticorpos para tigit
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
EP3432927A4 (en) * 2016-03-24 2019-11-20 Gensun Biopharma Inc. TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3039910A1 (en) 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same
MX2018011939A (es) 2016-03-29 2019-05-20 Stcube Inc Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos.
EP3452084A4 (en) 2016-05-02 2020-01-01 Tetragenetics, Inc. ANTI-KV 1.3 ANTIBODIES AND METHODS OF PRODUCING AND USING THE SAME
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US11083790B2 (en) 2016-06-02 2021-08-10 Bristol-Myers Squibb Company Treatment of Hodgkin lymphoma using an anti-PD-1 antibody
KR20190008962A (ko) 2016-06-02 2019-01-25 브리스톨-마이어스 스큅 컴퍼니 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도
JP2019517498A (ja) 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体
KR20190015408A (ko) 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
KR102515509B1 (ko) 2016-06-03 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
WO2017214182A1 (en) * 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
MA45192A (fr) * 2016-06-07 2019-04-10 Macrogenics Inc Traitement d'association
AU2017279046B2 (en) * 2016-06-10 2020-07-02 Novartis Ag Therapeutic uses of a c-Raf inhibitor
CN109563170B (zh) 2016-06-10 2023-10-13 瑞泽恩制药公司 抗gitr抗体及其用途
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
MX2018016364A (es) 2016-06-20 2019-11-28 Kymab Ltd Anticuerpos anti-pd-l1.
GB2569463A (en) * 2016-07-18 2019-06-19 Harvard College Human lymphoid tissue-on-chip
WO2018017673A1 (en) 2016-07-20 2018-01-25 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
MY189412A (en) * 2016-08-05 2022-02-10 Y Biologics Inc Antibody to programmed cell death 1 (pd-1) and use thereof
WO2018026248A1 (ko) * 2016-08-05 2018-02-08 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
EP3500294A4 (en) * 2016-08-22 2020-07-29 Arbutus Biopharma Corporation ANTI-PD-1 ANTIBODIES OR FRAGMENTS THEREOF FOR TREATING HEPATITIS B
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP2019531284A (ja) 2016-09-19 2019-10-31 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
EA201990285A1 (ru) 2016-09-29 2019-12-30 Бейджин Ханми Фармасьютикал Ко., Лтд. Гетеродимерные иммуноглобулиновые конструкции и способы их получения
PL3445787T3 (pl) 2016-10-07 2021-05-31 TCR2 Therapeutics Inc. Kompozycje i sposoby reprogramowania receptorów limfocytów t przy użyciu białek fuzyjnych
US20190315865A1 (en) 2016-10-28 2019-10-17 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
KR20190101364A (ko) 2016-11-01 2019-08-30 테사로, 인코포레이티드 예정 사멸-1(pd-1)에 대한 항체
AU2017355401A1 (en) 2016-11-02 2019-05-02 Jounce Therapeutics, Inc. Antibodies to PD-1 and uses thereof
BR112019008223A2 (pt) 2016-11-03 2019-07-16 Bristol-Myers Squibb Company anticorpos anti-ctla-4 ativáveis e usos dos mesmos
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017356860A1 (en) 2016-11-08 2019-05-16 Qilu Puget Sound Biotherapeutics Corporation Anti-PD1 and anti-CTLA4 antibodies
MX2019005858A (es) 2016-11-18 2019-08-12 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo.
US11359018B2 (en) 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
MY191926A (en) * 2016-12-01 2022-07-18 Regeneron Pharma Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
CN110168105A (zh) 2016-12-09 2019-08-23 瑞泽恩制药公司 用于对t细胞受体进行测序的系统和方法及其用途
JP7122758B2 (ja) * 2016-12-23 2022-08-22 アールイーエムディー バイオセラピューティクス，インコーポレイテッド プログラム死－１（ｐｄ－１）に結合する抗体を使用する免疫療法
CN106674209B (zh) * 2016-12-23 2020-03-06 深圳先进技术研究院 程序性死亡受体1基因抑制剂及其制备方法与应用
CN108203464B (zh) * 2016-12-25 2021-07-20 南京金斯瑞生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-1抗体
CN113480530A (zh) 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
WO2018128939A1 (en) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Checkpoint regulator antagonists
US11407830B2 (en) 2017-01-09 2022-08-09 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
EA201991729A1 (ru) * 2017-01-20 2019-12-30 Санофи Антитела к tgf-бета и их применение
TW202313678A (zh) 2017-01-20 2023-04-01 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
US20200237874A1 (en) 2017-01-20 2020-07-30 Novartis Ag Combination therapy for the treatment of cancer
WO2018133842A1 (zh) 2017-01-20 2018-07-26 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
AR110904A1 (es) * 2017-01-20 2019-05-15 Sanofi Sa ANTICUERPOS ANTI-TGF-b Y SU USO
KR20190115053A (ko) 2017-02-10 2019-10-10 노파르티스 아게 1-(4-아미노-5-브로모-6-(1h-피라졸-1-일)피리미딘-2-일)-1h-피라졸-4-올 및 암 치료에 있어서의 이의 용도
EP3580238A1 (en) 2017-02-10 2019-12-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
KR20240011262A (ko) 2017-02-21 2024-01-25 리제너론 파아마슈티컬스, 인크. 폐암의 치료를 위한 항-pd-1 항체
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
UY37621A (es) 2017-02-28 2018-09-28 Sanofi Sa Arn terapéutico que codifica citoquinas
CN110637031B (zh) * 2017-03-04 2024-04-16 湘潭腾华生物科技有限公司 程序性死亡蛋白1(pd-1)的重组抗体及其用途
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018246252A1 (en) * 2017-03-29 2019-09-19 Celgene Corporation Formulations comprising PD-1 binding proteins and methods of making thereof
KR20190133213A (ko) 2017-03-31 2019-12-02 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
SG11201909156RA (en) 2017-04-01 2019-10-30 Beijing hanmi pharm co ltd Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
PE20191494A1 (es) * 2017-04-03 2019-10-21 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
CA3055769A1 (en) 2017-04-03 2018-10-11 Oncologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
CN116375876A (zh) 2017-04-05 2023-07-04 豪夫迈·罗氏有限公司 特异性结合pd1和lag3的双特异性抗体
MA49042A (fr) 2017-04-05 2020-02-12 Symphogen As Polythérapies ciblant pd-1, tim-3 et lag-3
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
US11547741B2 (en) * 2017-05-22 2023-01-10 Oncoimmune, Inc. Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
CN110691795A (zh) 2017-05-30 2020-01-14 百时美施贵宝公司 包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
CA3060984A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JOP20190279A1 (ar) 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
JP2020522508A (ja) 2017-06-01 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を用いる腫瘍の治療方法
BR112019025574A2 (pt) 2017-06-05 2020-06-23 Janssen Biotech, Inc. Anticorpos que se ligam especificamente ao pd-1 e métodos de uso
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3641812A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
JP2020529862A (ja) * 2017-06-25 2020-10-15 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 抗ｐｄ−１抗体とその作製及び使用方法
CA3066747A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
EP3421494A1 (en) 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
SG11201912548XA (en) 2017-07-06 2020-01-30 Regeneron Pharma Cell culture process for making a glycoprotein
EP3652166A1 (en) 2017-07-14 2020-05-20 Innate Tumor Immunity, Inc. Nlrp3 modulators
US20200172617A1 (en) 2017-07-20 2020-06-04 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
JP7304846B2 (ja) * 2017-07-24 2023-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ８抗体およびその使用
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
KR20200032180A (ko) 2017-07-28 2020-03-25 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
EP3661556A4 (en) * 2017-07-29 2021-04-28 University of Southern California SYNTHETIC EXTRACELLULAR VESICLES FOR NEW THERAPIES
CN111164100B (zh) 2017-08-03 2024-03-12 美国安进公司 白介素-21突变蛋白和治疗方法
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
KR102651946B1 (ko) 2017-08-31 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
CN111032672A (zh) 2017-08-31 2020-04-17 百时美施贵宝公司 作为抗癌剂的环二核苷酸
US11021540B2 (en) * 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
SG11202002282TA (en) 2017-09-20 2020-04-29 Regeneron Pharma Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
CN111344297B (zh) 2017-10-10 2023-10-20 百时美施贵宝公司 作为抗癌剂的环二核苷酸
JP2020536894A (ja) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍処置法
KR20200065065A (ko) 2017-10-16 2020-06-08 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
CN111263771A (zh) * 2017-11-03 2020-06-09 诺华股份有限公司 用于治疗干燥综合征的抗cd40抗体
CN111213059B (zh) 2017-11-06 2024-01-09 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
CN111315397A (zh) 2017-11-06 2020-06-19 百时美施贵宝公司 治疗肿瘤的方法
WO2019090390A1 (en) * 2017-11-08 2019-05-16 University Of Canberra Immunogenic compositions and uses therefor
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
TW201925194A (zh) 2017-11-20 2019-07-01 美商雅里俊公司 吲哚化合物及其用途
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN109912577B (zh) * 2017-12-12 2021-10-22 深圳先进技术研究院 用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
EP3727629A1 (en) 2017-12-22 2020-10-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
EP3740506A1 (en) 2018-01-16 2020-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
SG11202006823XA (en) 2018-01-22 2020-08-28 Bristol Myers Squibb Co Compositions and methods of treating cancer
CA3096287A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
CA3090249A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
EA202091689A1 (ru) 2018-01-31 2020-10-22 Ридженерон Фармасьютикалз, Инк. Система и способ определения характеристик примесей, представляющих собой варианты, отличающиеся по размеру и заряду, в продукте, представляющем собой лекарственное средство
KR102171766B1 (ko) * 2018-02-02 2020-10-29 주식회사 뉴라클제네틱스 Pd-l1 결합력이 증대된 pd-1 변이체
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
GB201802573D0 (en) * 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
WO2019168774A1 (en) 2018-02-28 2019-09-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
AU2019227715B2 (en) 2018-02-28 2022-03-31 Ap Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
JP7250808B2 (ja) 2018-03-08 2023-04-03 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
IL307577A (en) 2018-03-19 2023-12-01 Regeneron Pharma In-house capillary electrophoresis tests and reagents
MX2020009550A (es) * 2018-03-22 2020-11-11 Keires Ag Proteinas de union a antigeno antagonistas.
EP3768277A1 (en) * 2018-03-23 2021-01-27 Isr Immune System Regulation Holding Ab (Publ) Combinations of macrolide compounds and immune checkpoint inhibitors
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
CN108546297B (zh) * 2018-03-29 2019-08-02 中国人民解放军军事科学院军事医学研究院 针对pd-1的单克隆抗体及其应用
CN111971306A (zh) 2018-03-30 2020-11-20 百时美施贵宝公司 治疗肿瘤的方法
WO2019195452A1 (en) 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN109336975B (zh) * 2018-04-18 2022-05-13 中国科学院微生物研究所 一种靶向pd-1的肿瘤抑制性抗体及其应用
CN112074516A (zh) 2018-04-25 2020-12-11 先天肿瘤免疫公司 Nlrp3调节剂
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
MX2020011684A (es) 2018-05-04 2020-12-10 Merck Patent Gmbh Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
WO2019219709A1 (en) 2018-05-14 2019-11-21 Immunocore Limited Bifunctional binding polypeptides
WO2019219064A1 (en) * 2018-05-17 2019-11-21 Nanjing Leads Biolabs Co.Ltd Antibody binding pd-1 and use thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3810109A4 (en) 2018-05-31 2022-03-16 Peloton Therapeutics, Inc. COMPOSITIONS AND METHODS FOR INHIBITING CD73
CN112384531A (zh) 2018-06-01 2021-02-19 诺华股份有限公司 针对bcma的结合分子及其用途
CN112351820A (zh) 2018-06-21 2021-02-09 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途
TW202005985A (zh) 2018-06-21 2020-02-01 美商再生元醫藥公司 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
TWI819011B (zh) 2018-06-23 2023-10-21 美商建南德克公司 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
US11795206B2 (en) 2018-06-24 2023-10-24 Yunbiao Lu Specific bifunctional BY-001 (active composition of homomultimer of chimeric protein pd-L1 / fc-gamma1) down regulates the activation of human immune cells and the use thereof
JP2021529556A (ja) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． 抗腫瘍アンタゴニスト
KR20210042909A (ko) * 2018-07-09 2021-04-20 프레시전 인코포레이티드 융합 구조물 및 그의 이용 방법
CA3103385A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2021530502A (ja) 2018-07-18 2021-11-11 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
CN112424231B (zh) * 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 抗pd-1抗体及其剂量和用途
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
JP2021532143A (ja) 2018-07-26 2021-11-25 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 癌の処置のためのｌａｇ−３併用療法
EP3837015B1 (en) 2018-08-16 2024-02-14 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
MX2021001581A (es) 2018-08-16 2021-04-19 Innate Tumor Immunity Inc Compuestos de 4-amino-1h-imidazo[4,5-c]quinolina sustituidos y metodos mejorados para su preparacion.
KR20210046023A (ko) 2018-08-16 2021-04-27 인네이트 튜머 이뮤니티, 인코포레이티드 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
TW202026423A (zh) 2018-08-24 2020-07-16 法商賽諾菲公司 用於實體瘤癌症的治療性ｒｎａ
BR112020024296A2 (pt) 2018-08-27 2021-03-09 Regeneron Pharmaceuticals, Inc. Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína
US20210246219A1 (en) 2018-08-27 2021-08-12 Pieris Pharmaceuticals Gmbh Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
EA202190032A1 (ru) 2018-08-30 2021-03-12 Ридженерон Фармасьютикалз, Инк. Способы определения характеристик белковых комплексов
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
CN112771077A (zh) 2018-08-31 2021-05-07 瑞泽恩制药公司 针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略
TW202024023A (zh) 2018-09-03 2020-07-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
KR20210072059A (ko) 2018-10-09 2021-06-16 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 항-MerTK 항체
EP3867409A1 (en) 2018-10-16 2021-08-25 Novartis AG Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
MX2021003903A (es) 2018-10-19 2021-06-04 Bristol Myers Squibb Co Terapia combinada para el melanoma.
JP2022505647A (ja) 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
MX2021005594A (es) * 2018-11-13 2021-10-22 Compass Therapeutics Llc Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
CN113038939A (zh) 2018-11-14 2021-06-25 瑞泽恩制药公司 损害内施用pd-1抑制剂用于治疗皮肤癌
EP3880708A1 (en) 2018-11-16 2021-09-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
TW202038943A (zh) 2018-11-19 2020-11-01 美商雅里俊公司 治療癌症之方法
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
MX2021006544A (es) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
EP3891508A1 (en) 2018-12-04 2021-10-13 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
EP3894401A2 (en) 2018-12-11 2021-10-20 Theravance Biopharma R&D IP, LLC Naphthyridine and quinoline derivatives useful as alk5 inhibitors
EP3898695A1 (en) 2018-12-19 2021-10-27 Regeneron Pharmaceuticals, Inc. Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
HUE063732T2 (hu) * 2018-12-19 2024-01-28 Humabs Biomed Sa Hepatitisz B vírust semlegesítõ antitestek és alkalmazásaik
MA54540A (fr) 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20200369762A1 (en) 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
KR20210108422A (ko) 2018-12-21 2021-09-02 노파르티스 아게 IL-1β 결합 항체의 용도
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
KR20210109564A (ko) 2018-12-21 2021-09-06 옹쎄오 신규의 컨쥬게이티드 핵산 분자 및 이의 용도
EP3899951A1 (en) 2018-12-23 2021-10-27 F. Hoffmann-La Roche AG Tumor classification based on predicted tumor mutational burden
WO2020140088A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-pd-1 binding proteins and methods of use thereof
JP2022517111A (ja) 2019-01-14 2022-03-04 イネイト・テューマー・イミュニティ・インコーポレイテッド がんの治療に用いるためのヘテロ環ｎｌｒｐ３モジュレーター
CN113286787A (zh) 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
WO2020150152A1 (en) 2019-01-14 2020-07-23 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
EP3911416A1 (en) 2019-01-14 2021-11-24 Innate Tumor Immunity, Inc. Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
CN113286786A (zh) 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
ES2942024T3 (es) 2019-01-16 2023-05-29 Regeneron Pharma Métodos para caracterizar enlaces disulfuro
TW202043274A (zh) 2019-01-21 2020-12-01 法商賽諾菲公司 用於晚期實性瘤癌症之治療性ｒｎａ及抗ｐｄ１抗體
WO2020160375A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
EP3923940A1 (en) 2019-02-12 2021-12-22 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
SG11202108089SA (en) * 2019-02-28 2021-08-30 Regeneron Pharma Administration of pd-1 inhibitors for treating skin cancer
JP2022523804A (ja) 2019-03-06 2022-04-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
JP2022519923A (ja) 2019-03-22 2022-03-25 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
KR20210142659A (ko) 2019-03-22 2021-11-25 리제너론 파아마슈티컬스, 인크. Egfr×cd28 다중특이성 항체
US20220041733A1 (en) 2019-03-28 2022-02-10 Bristol-Myers Squibb Company Methods of treating tumor
EP3946628A1 (en) 2019-03-28 2022-02-09 Bristol-Myers Squibb Company Methods of treating tumor
CN113710265A (zh) 2019-04-12 2021-11-26 脉管生物生长有限公司 抗肿瘤治疗的方法
CN113906021A (zh) 2019-04-15 2022-01-07 阿里根公司 手性吲哚化合物及其用途
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CN114364703A (zh) 2019-04-19 2022-04-15 豪夫迈·罗氏有限公司 抗mertk抗体及它们的使用方法
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
US20230295087A1 (en) 2019-05-13 2023-09-21 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
MX2021013815A (es) 2019-05-13 2021-12-14 Regeneron Pharma Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer.
US20230242478A1 (en) 2019-05-13 2023-08-03 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
JP2022534889A (ja) 2019-05-24 2022-08-04 ファイザー・インコーポレイテッド Ｃｄｋ阻害剤を使用した組合せ療法
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
US20220275088A1 (en) * 2019-06-14 2022-09-01 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
KR20220041080A (ko) 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
CN114206379A (zh) 2019-06-18 2022-03-18 爱尔兰詹森科学公司 乙型肝炎病毒(hbv)疫苗和抗pd-1抗体的组合
CN114340735A (zh) 2019-06-28 2022-04-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
MX2022000164A (es) 2019-07-03 2022-04-01 Sumitomo Pharma Oncology Inc Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
TW202328206A (zh) 2019-07-05 2023-07-16 日商小野藥品工業股份有限公司 以ｐｄ－１／ｃｄ３雙特異性蛋白質所進行之血液性癌症治療
CA3143478A1 (en) * 2019-07-09 2021-01-14 Tomer Hertz Antibodies with reduced immunogenicity
US20210032322A1 (en) * 2019-08-01 2021-02-04 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgf-beta and compositions therefor
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. DUAL SPECIFIC PROTEIN
US11629190B2 (en) 2019-08-15 2023-04-18 Oregon State University Canine antibody therapeutic for treating cancer
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CN114450028A (zh) 2019-09-22 2022-05-06 百时美施贵宝公司 Lag-3拮抗剂治疗的定量空间剖析
CA3216345A1 (en) 2019-09-24 2021-04-01 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
CN114728046A (zh) 2019-09-25 2022-07-08 思进公司 联合抗cd30 adc、抗pd-1和化疗以治疗血液癌症
JP2022549337A (ja) 2019-09-25 2022-11-24 ブリストル－マイヤーズ スクイブ カンパニー がん療法のための複合バイオマーカー
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
EP4055033A4 (en) * 2019-11-04 2023-12-06 Inovio Pharmaceuticals, Inc. COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CANCER
KR20220092578A (ko) 2019-11-05 2022-07-01 브리스톨-마이어스 스큅 컴퍼니 M-단백질 검정 및 이의 용도
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
MX2022004501A (es) 2019-11-07 2022-05-06 Oncxerna Therapeutics Inc Clasificacion de microambientes tumorales.
MX2022005474A (es) 2019-11-08 2022-06-02 Bristol Myers Squibb Co Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3).
MX2022005775A (es) 2019-11-13 2022-06-09 Genentech Inc Compuestos terapeuticos y metodos de uso.
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
US20230000864A1 (en) 2019-11-22 2023-01-05 Sumitomo Pharma Oncology, Inc. Solid dose pharmaceutical composition
KR20220104208A (ko) 2019-11-22 2022-07-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린
CA3158119A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CA3164124A1 (en) 2019-12-09 2021-06-17 Seagen Inc. Combination therapy with liv1-adc and pd-1 antagonist
KR20220118481A (ko) 2019-12-19 2022-08-25 브리스톨-마이어스 스큅 컴퍼니 Dgk 억제제 및 체크포인트 길항제의 조합물
CN115052662A (zh) 2019-12-20 2022-09-13 诺华股份有限公司 抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
EP4079763A4 (en) * 2019-12-20 2023-10-11 Guangdong Feipeng Pharmaceutical Co., Ltd MONOCLONAL ANTIBODY AGAINST HUMAN PROGRAMMED DEATH-1 (PD-1)
KR20220127848A (ko) 2020-01-10 2022-09-20 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
BR112022014212B1 (pt) 2020-01-21 2024-01-23 Regeneron Pharmaceuticals, Inc Métodos de análise de uma amostra incluindo uma proteína de interesse
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
BR112022014962A2 (pt) 2020-01-30 2022-09-20 Ona Therapeutics S L Terapia de combinação para tratamento de câncer e metástase de câncer
CN115397459A (zh) 2020-01-31 2022-11-25 基因泰克公司 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
KR20220139915A (ko) 2020-02-06 2022-10-17 브리스톨-마이어스 스큅 컴퍼니 Il-10 및 그의 용도
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
AU2021225491A1 (en) 2020-02-28 2022-10-20 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
CA3168173A1 (en) 2020-03-06 2021-09-10 Robert Babb Anti-gitr antibodies and uses thereof
WO2021176424A1 (en) 2020-03-06 2021-09-10 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
CN115484958A (zh) 2020-03-06 2022-12-16 赛尔基因昆蒂赛尔研究公司 用于治疗sclc或sqnsclc的lsd-1抑制剂和纳武单抗的组合
WO2021194942A1 (en) 2020-03-23 2021-09-30 Bristol-Myers Squibb Company Anti-ccr8 antibodies for treating cancer
US20230107609A1 (en) * 2020-03-26 2023-04-06 Cureimmune Therapeutics Inc. Anti-pd-1 antibodies and methods of use
US11673879B2 (en) 2020-03-31 2023-06-13 Theravance Biopharma R&D Ip, Llc Substituted pyrimidines and methods of use
MX2022013031A (es) 2020-04-21 2023-01-04 Novartis Ag Regimen de dosificacion para el tratamiento de una enfermedad modulada por csf-1r.
CA3176515A1 (en) 2020-04-22 2021-10-28 Merck Sharp & Dohme Llc Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer
EP4157464A1 (en) 2020-05-26 2023-04-05 Regeneron Pharmaceuticals, Inc. Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab
WO2021243028A1 (en) * 2020-05-27 2021-12-02 Dana-Farber Cancer Institute, Inc. Bispecific molecules for selectively modulating t cells
EP4157875A1 (en) 2020-06-02 2023-04-05 Arcus Biosciences, Inc. Antibodies to tigit
WO2021253041A1 (en) 2020-06-10 2021-12-16 Theravance Biopharma R&D Ip, Llc Naphthyridine derivatives useful as alk5 inhibitors
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022046833A1 (en) 2020-08-26 2022-03-03 Regeneron Pharmaceuticals, Inc. Methods of treating cancer by administering a pd-1 inhibitor
BR112023003427A2 (pt) 2020-08-28 2023-03-21 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para carcinoma hepatocelular
AU2021332355A1 (en) 2020-08-31 2023-03-23 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
JP2023538955A (ja) 2020-08-31 2023-09-12 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在シグネチャーおよび免疫療法
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4208482A1 (en) 2020-09-02 2023-07-12 Pharmabcine Inc. Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
JP2023542490A (ja) 2020-09-03 2023-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することによりがん疼痛を処置する方法
BR112023001864A2 (pt) 2020-09-14 2023-03-28 Boehringer Ingelheim Int Vacina de reforço primário heteróloga
EP4214234A1 (en) 2020-09-18 2023-07-26 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
BR112023005377A2 (pt) 2020-09-24 2023-04-25 Merck Sharp & Dohme Llc Formulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e variantes de hialuronidase e fragmentos das mesmas e métodos de uso das mesmas
US20230374160A1 (en) 2020-10-02 2023-11-23 Regeneron Pharmaceuticals, Inc. Combination of antibodies for treating cancer with reduced cytokine release syndrome
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
EP4232019A1 (en) 2020-10-23 2023-08-30 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
AU2021369590A1 (en) 2020-10-28 2023-06-22 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
KR20230095119A (ko) 2020-11-04 2023-06-28 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약
CA3196191A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022104043A1 (en) * 2020-11-13 2022-05-19 Ludwig Institute For Cancer Research Ltd Pd-1 decoy variants for immunotherapy
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
CA3202523A1 (en) 2020-12-02 2022-06-09 Genentech, Inc. Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
JP2023553210A (ja) * 2020-12-15 2023-12-20 バイカラ セラピューティクス インコーポレイテッド がんの処置のための併用療法
US20220257707A1 (en) 2020-12-17 2022-08-18 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
CA3201348A1 (en) 2020-12-28 2022-07-07 Masano HUANG Antibody compositions and methods of use thereof
AU2022209730A1 (en) 2021-01-20 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
EP4281102A1 (en) 2021-01-22 2023-11-29 Mendus B.V. Methods of tumor vaccination
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
CA3170208A1 (en) 2021-02-11 2022-08-18 Elizabeth Miller Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor
AU2022230987A1 (en) 2021-03-03 2023-08-31 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
AU2022235341A1 (en) 2021-03-12 2023-09-21 Mendus B.V. Methods of vaccination and use of cd47 blockade
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
WO2022204672A1 (en) 2021-03-23 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
CA3213049A1 (en) 2021-03-25 2022-09-29 Laura E. BENJAMIN Targeted therapies in cancer
BR112023018665A2 (pt) 2021-03-26 2023-10-03 Regeneron Pharma Métodos e sistemas para desenvolvimento de protocolos de mistura
IL307262A (en) 2021-03-29 2023-11-01 Juno Therapeutics Inc METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
JP2024516230A (ja) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド がんのための治療及び診断方法並びに組成物
KR20240005691A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022251853A1 (en) 2021-05-25 2022-12-01 Edelweiss Immune Inc C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
TW202314240A (zh) 2021-06-01 2023-04-01 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
EP4346904A1 (en) 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
US20230036928A1 (en) 2021-06-18 2023-02-02 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
US20230051304A1 (en) 2021-07-19 2023-02-16 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2023004287A1 (en) 2021-07-19 2023-01-26 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
CA3224180A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
CA3226281A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
WO2023022965A2 (en) 2021-08-16 2023-02-23 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
CA3234647A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
US20230116199A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
IL309227A (en) 2021-10-29 2024-02-01 Bristol Myers Squibb Co LAG-3 antagonist therapy for hematological cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023084445A1 (en) 2021-11-12 2023-05-19 Novartis Ag Combination therapy for treating lung cancer
US20230203062A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
TW202332429A (zh) 2021-11-24 2023-08-16 美商建南德克公司 治療性化合物及其使用方法
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023133280A1 (en) 2022-01-07 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
WO2023159102A1 (en) 2022-02-17 2023-08-24 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023177772A1 (en) 2022-03-17 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
TW202346856A (zh) 2022-03-18 2023-12-01 美商里珍納龍藥品有限公司 分析多肽變體的方法及系統
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN116925223A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pd-1单克隆抗体及其衍生物和用途
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
US20230326022A1 (en) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023224912A1 (en) 2022-05-16 2023-11-23 Regeneron Pharmaceuticals, Inc. Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
US20230416396A1 (en) 2022-05-18 2023-12-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
US20230382969A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023235848A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
WO2024018069A1 (en) 2022-07-22 2024-01-25 Philogen S.P.A Anti-cd28 antibodies
WO2024023740A1 (en) 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
WO2024030453A1 (en) 2022-08-02 2024-02-08 Regeneron Pharmaceuticals, Inc. Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma
WO2024076926A1 (en) 2022-10-03 2024-04-11 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
CA2414331C (en) 2000-06-28 2011-11-29 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
JP2004104681A (ja) 2002-09-12 2004-04-02 Renesas Technology Corp 入力バッファ回路
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
EP2270051B1 (en) * 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Antibody specific for human PD-1 and CD3
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
WO2007100098A1 (ja) 2006-03-03 2007-09-07 Kyoto University 細胞表面機能分子の細胞外領域多量体
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009024531A1 (en) 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
CA2698419C (en) 2007-09-07 2019-11-12 Edward Dolk Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
ES2639857T3 (es) 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR101001360B1 (ko) 2008-06-16 2010-12-14 (주)기가레인 전자 기기의 접지에 전기적으로 연결되는 인쇄회로기판
DK2350129T3 (en) 2008-08-25 2015-08-31 Amplimmune Inc PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
MY164121A (en) 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
CN102740887B (zh) 2009-09-30 2015-04-15 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
KR101790767B1 (ko) 2009-11-24 2017-10-26 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
LT3095871T (lt) 2010-02-08 2019-05-27 Regeneron Pharmaceuticals, Inc. Bendros lengvosios grandinės pelė
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
EP2910572B1 (en) 2010-11-11 2017-09-06 Versitech Limited Soluble pd-1 variants, fusion constructs, and uses thereof
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
CA2899433A1 (en) 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
CN104302169B (zh) * 2012-03-16 2017-11-17 瑞泽恩制药公司 组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物
EP3511343A1 (en) 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
US20130303250A1 (en) 2012-05-11 2013-11-14 Ryan Moore Method of Playing a Card Game
BR112014028826A8 (pt) 2012-05-15 2021-07-20 Bristol Myers Squibb Co anticorpos monoclonais, uso de anticorpos anti-pd1, anti-pd-l1 e anti-ctla-4 em imunoterapia e tratamento de câncer, bem como kits e processo de seleção de indivíduo para tratamento com anticorpo anti-pd-1
BR112014029887A8 (pt) 2012-05-31 2021-09-14 Genentech Inc Método para tratar ou retardar a progressão do câncer, kits e uso de um antagonista de ligação do eixo pd-1, oxaliplatina, leucovorina e 5-fu
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
PL2904011T3 (pl) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2014127917A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
RU2019129525A (ru) 2013-07-16 2019-11-05 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
CA2917858A1 (en) 2013-08-02 2015-02-05 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CA2920113A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
ES2728578T3 (es) 2013-09-20 2019-10-25 Bristol Myers Squibb Co Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
HUE047194T2 (hu) 2013-09-27 2020-04-28 Hoffmann La Roche Anti-PDL1 antitest készítmények
PE20210648A1 (es) 2013-12-17 2021-03-26 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TN2017000129A1 (en) 2014-10-14 2018-10-19 Dana Farber Cancer Inst Inc Antibody molecules to pd-l1 and uses thereof
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EA201890285A1 (ru) * 2015-07-13 2018-08-31 Сайтомкс Терапьютикс, Инк. Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MA44146B1 (fr) 2015-12-22 2023-10-31 Regeneron Pharma Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation

Also Published As

Publication number Publication date
TWI681969B (zh) 2020-01-11
JP6425730B2 (ja) 2018-11-21
WO2015112800A1 (en) 2015-07-30
EP3967710A1 (en) 2022-03-16
US20200330794A1 (en) 2020-10-22
CY1124747T1 (el) 2022-07-22
AU2015209233B2 (en) 2020-03-05
CA3207270A1 (en) 2015-07-30
IL267798B (en) 2020-09-30
MX2016009554A (es) 2016-11-17
BR112016016699A2 (pt) 2017-10-03
JP2022160558A (ja) 2022-10-19
US9987500B2 (en) 2018-06-05
IL246818A0 (en) 2016-08-31
ES2888224T3 (es) 2022-01-03
JP2019038823A (ja) 2019-03-14
DK3097119T3 (en) 2021-09-27
PL3097119T3 (pl) 2022-01-03
LT3097119T (lt) 2021-10-11
US10737113B2 (en) 2020-08-11
PH12016501330B1 (en) 2016-08-15
KR20210152583A (ko) 2021-12-15
JP2020146050A (ja) 2020-09-17
EP3097119B1 (en) 2021-08-25
BR122022010183B1 (pt) 2024-01-30
EA034770B8 (ru) 2020-07-10
KR102337042B1 (ko) 2021-12-08
CA2936075C (en) 2023-09-19
JP6711883B2 (ja) 2020-06-17
EP3097119A1 (en) 2016-11-30
CA2936075A1 (en) 2015-07-30
HRP20211794T1 (hr) 2022-03-18
NZ722342A (en) 2022-05-27
MY176475A (en) 2020-08-11
IL267798A (en) 2019-09-26
RS62507B1 (sr) 2021-11-30
MX2021003436A (es) 2021-06-15
UA122666C2 (uk) 2020-12-28
IL246818B (en) 2019-07-31
PT3097119T (pt) 2021-09-29
EA201691482A1 (ru) 2016-11-30
CN106068275B (zh) 2021-06-01
AU2015209233A1 (en) 2016-08-04
PH12016501330A1 (en) 2016-08-15
UY35964A (es) 2015-08-31
CN106068275A (zh) 2016-11-02
US20180185668A1 (en) 2018-07-05
TW201540726A (zh) 2015-11-01
US20150203579A1 (en) 2015-07-23
KR20160132010A (ko) 2016-11-16
MX2021009852A (es) 2021-09-10
HUE056332T2 (hu) 2022-02-28
CN113248614A (zh) 2021-08-13
JP2017505125A (ja) 2017-02-16
SG11201605482SA (en) 2016-08-30
EA034770B1 (ru) 2020-03-18
CL2016001871A1 (es) 2017-05-19
JP7174009B2 (ja) 2022-11-17

Similar Documents

Publication Publication Date Title
IL267798B (en) Human antibodies to pd-1
IL285287B1 (en) Antibodies to tigit
IL246661B (en) Human antibodies to pd–l1
IL261188A (en) Antibodies against tigit
HK1252666A1 (zh) 針對cd40的抗體
IL249187B (en) Antibodies to il-15
PT3101132T (pt) Anticorpo humano anti-transtirretina
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
GB201421430D0 (en) Antibodies to Adam17 and uses thereof
GB2522473B (en) Improvements to windposts
GB2520781B (en) Improvements to hydro-turbines
GB201405489D0 (en) Able to go
GB201414608D0 (en) Improvements to structure
GB201421580D0 (en) Novel addition to an OTEC system